Pharmaceuticals

Lighten and Datavant have teamed up to turn messy medical notes into regulatory-grade data, aiming to dramatically speed up life sciences research.

Alaunos Therapeutics reports positive preclinical data for its oral metabolic drug, but with a perilous financial runway, the race for survival is on.

A strategic investment from Olayan Financing Company positions MS Pharma to dominate the MENA biologics market, fueling Saudi Arabia's Vision 2030 goals.

Biotheryx's novel protein degrader, BTX-9341, shows impressive safety and efficacy in patients who have progressed on standard therapies.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.

AI hardware innovator Cerebras Systems closes a massive $6.38B IPO, signaling a new front in the battle against NVIDIA with its unique wafer-scale chip.

The life sciences news hub earned prestigious Neal and Azbee National Gold awards, highlighting the growing influence of expert-driven B2B journalism.

New data reveals TARA-002 has a 55% complete response rate at one year for NMIBC, offering a promising, safer alternative to standard care.

A new oral drug for depression shows rapid, robust effects in a key trial, offering hope for millions by targeting a different brain pathway.

Pharma veteran Shyamakant Giri takes the helm at Apothecon Group, signaling an aggressive push into global regulated markets backed by Everstone Capital.

Out of 600+ plans, Alignment Health is one of just four to earn a top award for medication quality. Here's what that means for seniors and the industry.

Edesa Biotech pushes its pipeline forward with a new vitiligo trial and promising ARDS data, but rising R&D costs highlight the high stakes of innovation.

The Nexus Forum launches to connect China's booming biotech scene with global pharma, capitalizing on a major shift in worldwide drug discovery and deal-making.

NFL legend Brett Favre reports gains from an experimental Parkinson's drug, but what does the science say about this potential breakthrough treatment?

An ambitious challenge aims to turn Amazon biodiversity into sustainable businesses, betting that entrepreneurship is the key to the rainforest's survival.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

Fresh off its IPO, Agomab Therapeutics is presenting key data for its new IPF drug, AGMB-447, while courting investors on a multi-conference tour.

Wellcome and Nature launch the world's largest mental health prize, aiming to spark a revolution in a field plagued by underfunding and access gaps.